Speaker:

Kate Saylor, Ph.D, MS, Assistant Professor, Geisinger - has nothing to disclose.

Adam Buchanan, MS, MPH, CGC, Director of Genomic Medicine

Moderator:

Dan Hoegen, LSW,HEC-C, Clinical Ethicist, Geisinger - has nothing to disclose.

Learning Objectives:

At the conclusion of this session, the participant should be able to:
1) Clinical value: Understand the clinical potential of MCD screening, including the performance of MCD tests and diagnostic evaluation after a positive result
2) Health disparities: Identify the potential impacts of MCD testing on cancer disparities
3) Geisinger trial experience: Learn about Geisinger DETECT - A study outcomes, including detection rates, clinical relevance of positive screening, and patient experiences
 

Disclosure of Relevant Financial Relationships with/without Commercial Interests:


The Planning Committee consisting of Daniel Hoegen, LSW, HEC-C; Michelle Meyer, PhD, JD; F. Daniel Davis, PhD, HEC-C; Sharon Gray, MA, BSN, RN, HEC-C; Christopher Chabris, PhD; Greg Burke, MD; John Pagnotto, MD; Elizabeth McDonald, RD; Linda Page, RT; Ronald Napikoski, RT; Dean Parry, RPh; Kaylee Kachurka, PA-C; Erin Hall, PsyD and Anne Kasper have no identified disclosures.


CE Committee Member/Content Reviewers have nothing to disclose.


Any/All relevant financial relationships have been mitigated.

Content Disclosure:

This presentation/content is HIPPA compliant.

Commercial Support for this Session

None 

 

Session date: 
11/06/2024 - 4:00pm to 5:00pm EST
Location: 
Weiss Conference Room
Danville, PA
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AAPA Category I CME
  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Approved for APA Credit
  • 1.00 ASWB
  • 1.00 CDR
  • 1.00 Participation Credit

Please login or register to take this course.